Drug Topics
JANUARY 15, 2024
Data has indicated a potential association between COVID-19 vaccination and menstruation, but there is little evidence about this association based on chart-reviewed medical record data.
Pharmacy Times
JANUARY 15, 2024
In 2024, Pharmacy Practice in Focus: Health Systems welcomes the launch of the peer-review process, with this issue containing our first peer-reviewed paper.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JANUARY 15, 2024
A new study found that a universal coronavirus vaccine would be cost saving as long as it had an efficacy and coverage of 10% or more.
Pharmacy Times
JANUARY 15, 2024
Language barriers between pharmacists and patients impacts medication adherence, patient education, and overall health outcomes, resulting in patient harm.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JANUARY 15, 2024
Patients using a predictive alarm saw a reduction of more than 40% in time spent below range in hypoglycemia and more than 60% in time spent in severe hypoglycemia.
Pharmacy Times
JANUARY 15, 2024
The approval was based on the results of a phase 3 trial that found an improvement in progression-free survival among individuals treated with pembrolizumab.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 15, 2024
Biosimilars are proven to be highly similar to the original products with no clinical meaningful differences.
Pharmaceutical Commerce
JANUARY 15, 2024
FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.
pharmaphorum
JANUARY 15, 2024
Researchers at the University of Cambridge and Pfizer have developed an AI-powered approach to make it easier to design and make pharma molecules
European Pharmaceutical Review
JANUARY 15, 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree ® (vamorolone), as a safer alternative to corticosteroids, for Duchenne muscular dystrophy (DMD). “In addition to its anti-inflammatory efficacy, both the EMA and the MHRA recognise the benefits of treatment with Agamree for bone health and growth,” Dr Shabir Hasham, Chief Medical Officer of Santhera Pharmaceuticals shared.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 15, 2024
MSD’s Keytruda has been cleared by the FDA as the first PD-1 inhibitor for newly diagnosed cervical cancer patients with less severe disease
Pharmacy Times
JANUARY 15, 2024
2023 was an impactful year for the field of oncology pharmacy.
pharmaphorum
JANUARY 15, 2024
Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.
European Pharmaceutical Review
JANUARY 15, 2024
The natural polymer tara gum polysaccharide ( Caesalpinia spinosa ) has application potential in pharmaceutical drug delivery , according to researchers in Korea. This is mainly due to its benefits such as its biocompatibility, biodegradability, and safety. A biodegradable alternative A study by the researchers, published in Carbohydrate Polymers , suggested that the material could be a natural, environmentally-friendly alternative to petroleum-based polymers such as plastic.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JANUARY 15, 2024
Germany’s IG BCE trade union has pushed back against any break-up of Bayer, claiming it could put thousands of domestic jobs at risk
Outsourcing Pharma
JANUARY 15, 2024
Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.
pharmaphorum
JANUARY 15, 2024
True innovation in life sciences is only possible through a connected, pan-European approach Mike.
Pharmacy Times
JANUARY 15, 2024
Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.
Pharmafile
JANUARY 15, 2024
Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of the company’s Denosumab injections (BA6101 and BA1102). The study will take place in Europe, the US and Japan, with a meeting having recently been held in Germany to share results from a phase 1 pharmacokinetic […] The post Boan Biotech completes enrolment for phase 3 study of Denosumab appeared first on Pharmafile.
Pharmacy Times
JANUARY 15, 2024
Biermaas said her team is continuing to focus on product availability globally, as well as the massive growth in GLP-1 diabetes and weight loss treatments.
Outsourcing Pharma
JANUARY 15, 2024
Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.
Pharmacy Times
JANUARY 15, 2024
In addition to the current principles and treatment regimens, there are upcoming data on myelofibrosis drugs that could be reported as early as 2024.
Outsourcing Pharma
JANUARY 15, 2024
SGD Pharma has announced its goal to become the global market leader in primary pharmaceutical glass packaging.
pharmaphorum
JANUARY 15, 2024
Orion buys stake in LegoChem amid pivot to cancer and pain Phil.
Outsourcing Pharma
JANUARY 15, 2024
Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.
pharmaphorum
JANUARY 15, 2024
Artificial intelligence (AI) is transforming the healthcare industry, particularly in decision-making and therapeutic advancements. Learn how AI will revolutionise healthcare and impact future decision-making processes in this informative article.
Outsourcing Pharma
JANUARY 15, 2024
Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.
Pharmafile
JANUARY 15, 2024
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. The approval follows data from the phase 3 KEYNOTE-A18 trial, […] The post FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment appeared first on Pharmafi
Pharmaceutical Commerce
JANUARY 15, 2024
The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.
PharmExec
JANUARY 15, 2024
The FDA issued the 39th overall approval for Keytruda (pembrolizumab), with the latest in combination with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.
BioPharm
JANUARY 15, 2024
The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.
PharmExec
JANUARY 15, 2024
Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.
Pharmaceutical Technology
JANUARY 15, 2024
MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.
PharmExec
JANUARY 15, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Expert insights. Personalized for you.
186 
Let's personalize your content